- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05456854
Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp
July 12, 2022 updated by: Stephanie B. Seminara, MD, Massachusetts General Hospital
The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an hyperglycemic clamp
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Assignment: Each study subject will serve as their own control. The order of the visits will be randomized.
Delivery of Interventions:
Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories.
During the inpatient study, the subjects will
Undergo a 16-hour kisspeptin infusion Undergo a hyperglycemic clamp
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Margaret Lippincott
- Phone Number: 617-726-8434
- Email: MGHKisspeptinResearch@partners.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Margaret Lippincott
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
- over the age of 17
- normal pubertal development
- regular menstrual cycles
- stable weight for previous three months
- normal body mass index
- blood pressure systolic BP < 140 mm Hg, diastolic < 90 mm Hg
- normal hemoglobin
- hemoglobin A1C < 6.5%
- BUN, creatinine not elevated
- AST, ALT < 3x upper limit of normal
- negative serum pregnancy test
Exclusion Criteria:
- active illicit drug use,
- history of a medication reaction requiring emergency medical care,
- difficulty with blood draws.
- history of hypertension, diabetes, heart disease, high cholesterol, cancer, or clotting disorders.
- history of chronic disease that has required hospitalization
- recent use of prescription medications which interfere with metabolism or reproduction (recent = within 5 half-lives of the drug) unless it is birth control
- history of diabetes in a first degree relative
- hyperlipidemia by fasting lipid panel
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Kisspeptin
Intravenous administration of kisspeptin 112-121 x 16 hours
|
Administration of a hyperglycemic clamp
Administration of kisspeptin-10 * 16 hr
|
PLACEBO_COMPARATOR: Placebo
Intravenous administration of placebo x 16 hours
|
Administration of a hyperglycemic clamp
Administration of placebo *16 hr
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First Phase Insulin Secretion
Time Frame: 10 minutes
|
Average Change in First Phase Insulin Secretion Between Kisspeptin and Placebo Arms
|
10 minutes
|
Second Phase Insulin Secretion
Time Frame: 2 hours
|
Average Change in Second Phase Insulin Secretion Between Kisspeptin and Placebo Arms
|
2 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Margaret Lippincott, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 3, 2022
Primary Completion (ANTICIPATED)
August 1, 2024
Study Completion (ANTICIPATED)
August 1, 2024
Study Registration Dates
First Submitted
July 8, 2022
First Submitted That Met QC Criteria
July 8, 2022
First Posted (ACTUAL)
July 13, 2022
Study Record Updates
Last Update Posted (ACTUAL)
July 14, 2022
Last Update Submitted That Met QC Criteria
July 12, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 267335
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Disease
-
Yonsei UniversityUnknownCardiovascular Disease | Metabolic DiseaseKorea, Republic of
-
Clinical Nutrition Research Centre, SingaporeCompletedCardiovascular Disease | Metabolic Disease
-
San Diego State UniversityNot yet recruitingBone Disease, Metabolic
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
The Hospital for Sick ChildrenRare Disease Foundation, Vancouver, CanadaCompleted
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
-
Shenzhen Center for Chronic Disease ControlCompletedNutrition Disorders | Genetic Predisposition to Disease | Metabolic DiseaseChina
-
National Institutes of Health Clinical Center (CC)CompletedVascular Diseases | Cancer | Metabolic Bone Disease | Inflammatory DiseaseUnited States
-
Istituto Ortopedico GaleazziUnknownPhysical Activity | Bone Disease, MetabolicItaly
-
Stanley Dudrick's Memorial HospitalCompletedMetabolic Bone DiseasePoland
Clinical Trials on Hyperglycemic Clamp
-
University Hospital Inselspital, BerneCompletedDiabetes Mellitus, Type 1 | ExerciseSwitzerland
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of Maryland, BaltimoreNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Yale UniversityWithdrawnDiabetes Mellitus | Fibrous Dysplasia | McCune-Albright Syndrome | Intraductal Papillary Mucinous NeoplasmUnited States
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 1 Diabetes MellitusUnited States
-
Adrian VellaRecruitingType2diabetesUnited States
-
University Hospital, GasthuisbergJuvenile Diabetes Research Foundation; Fund for Scientific Research, Flanders...UnknownKidney Transplantation | Pancreas TransplantationBelgium
-
Nemours Children's ClinicCompletedHyperglycemia | Obesity | Type 2 Diabetes Mellitus | Insulin Resistance | Pediatric Obesity | DysglycemiaUnited States
-
Diabeteszentrum Bad Lauterberg im HarzCompleted
-
Universitair Ziekenhuis BrusselJuvenile Diabetes Research Foundation; Vrije Universiteit BrusselRecruitingType1 Diabetes MellitusBelgium